Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | +2.62% | -0.42% | -53.00% |
03-15 | AC Immune Files $350 Million Mixed Shelf | MT |
03-14 | AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Chart calendar AC Immune SA
Upcoming events on AC Immune SA
Past events on AC Immune SA
24/04/2024 | Q1 2024 Earnings Release (Projected) |
14/03/2024 11:00 | Q4 2023 Earnings Release |
09/03/2024 17:25 | Alzheimer and Parkinson Diseases International Conference - Dymitr Kostrica |
08/03/2024 14:20 | Alzheimer and Parkinson Diseases International Conference - Tamara Seredenina |
08/03/2024 14:05 | Alzheimer and Parkinson Diseases International Conference - Damien Nevoltris |
08/03/2024 08:55 | Alzheimer and Parkinson Diseases International Conference - Marija Vukicevic |
06/03/2024 10:05 | Alzheimer and Parkinson Diseases International Conference - Nuno Mendonça |
06/03/2024 09:45 | Alzheimer and Parkinson Diseases International Conference - Elpida Tsika |
06/03/2024 09:25 | Alzheimer and Parkinson Diseases International Conference - Fabrizio Stocchi |
06/03/2024 09:10 | Alzheimer and Parkinson Diseases International Conference - Francesca Capotosti |
06/03/2024 08:45 | Alzheimer and Parkinson Diseases International Conference - Werner Poewe |
04/03/2024 | Alzheimer and Parkinson Diseases International Conference - Poster Number: P0215 / #1422 |
04/03/2024 | Alzheimer and Parkinson Diseases International Conference - Poster Number: P0114 / #1470 |
04/03/2024 | Alzheimer and Parkinson Diseases International Conference - Poster Number: P0996 / #1513 |
16/11/2023 11:30 | Jefferies London Healthcare Conference |
09/11/2023 15:00 | Investor Meeting - Key Opinion Leader |
03/11/2023 11:00 | Q3 2023 Earnings Release |
24/10/2023 | Clinical Trials on Alzheimer Disease Conference - Poster Number: LP031 |
24/10/2023 | Clinical Trials on Alzheimer Disease Conference - Poster Number: P147 |
24/10/2023 | Clinical Trials on Alzheimer Disease Conference - Poster Number: LP130 |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million CHF | Released Forecast Spread | 111 111 -0.24% | 15,4 15,6 -1.37% | 0,00 42,3 - | 3,94 5,59 -29.64% | 14,8 10,0 47.52% | 8,33 |
EBITDA Million CHF | Released Forecast Spread | 45,8 50,7 -9.64% | -59,3 -58,6 -1.18% | -76,6 -77,8 1.54% | -68,5 -78,2 12.42% | -51,4 -52,6 2.26% | -72,5 |
EBIT Million CHF | Released Forecast Spread | 44,5 46,9 -5.09% | -61,3 -59,5 -2.94% | -79,0 -75,8 -4.24% | -70,8 -75,3 5.98% | -53,6 -64,4 16.69% | -67,8 |
Earnings before Tax (EBT) Million CHF | Released Forecast Spread | 45,4 48,6 -6.49% | -61,9 -59,5 -4.09% | -73,0 -71,0 -2.8% | -70,7 -74,9 5.58% | -54,2 -64,0 15.23% | -67,6 |
Net income Million CHF | Released Forecast Spread | 45,4 48,6 -6.49% | -61,9 -59,5 -4.09% | -73,0 -44,8 -62.81% | -70,8 -73,5 3.74% | -54,2 -60,0 9.68% | -66,6 |
EPS CHF | Released Forecast Spread | 0,64 0,69 -7.18% | -0,86 -0,81 -5.64% | -0,97 -0,60 -60.42% | -0,85 -0,88 2.93% | -0,64 -0,71 9.65% | -0,66 |
Announcement Date | 30/03/20 | 23/03/21 | 22/03/22 | 16/03/23 | 14/03/24 | - |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million CHF | Released Forecast Spread | 0,00 42,2 - | 0,00 0,35 - | 0,00 0,35 - | 3,93 0,35 1024% | 0,00 1,60 -99.94% | 0,00 0,00 - | 0,00 1,67 - | 0,00 21,2 - | 14,8 10,0 47.52% | 5,33 | 0,50 | 0,50 | 3,50 |
EBIT Million CHF | Released Forecast Spread | -22,8 -19,7 -15.86% | -18,8 -18,6 -1.14% | -19,9 -18,7 -6.04% | -13,5 -19,4 30.6% | -18,7 -21,9 14.78% | -17,6 -18,9 7.18% | -17,0 -18,7 8.97% | -15,5 -17,8 12.96% | -3,54 -11,7 69.84% | -10,8 | -18,5 | -18,8 | -19,0 |
Earnings before Tax (EBT) Million CHF | Released Forecast Spread | -21,3 -19,4 -9.55% | -18,8 -18,5 -1.77% | -19,6 -18,7 -4.87% | -13,5 -19,1 29.26% | -18,7 -21,5 12.75% | -17,5 -18,9 7.51% | -16,8 -18,6 9.4% | -15,1 -17,8 14.8% | -4,74 -11,6 59.26% | -11,0 | -18,3 | -18,7 | -18,9 |
Net income Million CHF | Released Forecast Spread | -21,3 6,86 -410.36% | -18,8 -19,3 2.23% | -19,6 -19,8 0.86% | -13,5 -20,4 33.63% | -18,7 -20,6 9.11% | -17,5 -19,2 8.87% | -16,8 -17,1 1.48% | -15,1 2,41 -728.63% | -4,74 -8,26 42.58% | -13,1 | -18,1 | -18,4 | -16,6 |
EPS CHF | Released Forecast Spread | -0,26 0,10 -360% | -0,23 -0,22 -3.92% | -0,23 -0,24 2.95% | -0,16 -0,23 30.43% | -0,23 -0,25 9.09% | -0,21 -0,23 9.29% | -0,20 -0,19 -2.74% | -0,18 0,02 -985.39% | -0,05 -0,11 55.36% | -0,14 | -0,19 | -0,19 | -0,18 |
Announcement Date | 22/03/22 | 28/04/22 | 28/07/22 | 28/10/22 | 16/03/23 | 28/04/23 | 04/08/23 | 03/11/23 | 14/03/24 | - | - | - | - |
Past sector events for AC Immune SA
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ACIU Stock
- Calendar AC Immune SA